Oxford, UK based Accession Therapeutics raised $40M from existing investors today to further develop its precision viral delivered immunotherapies. The first program induces cancer cells to make PD-L1

Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is designed to bypass healthy tissue and only target tumor cells (without the need for screening). It targets the integrin αvβ6.